RTsafe was established in 2014 to commercialize the internationally patented PseudoPatient® idea. The basic component of which is to build an exact replica of patient’s head to be radiotherapy treated and tested, before his/her actual treatment, aiming to verify and secure the safety and quality of life of the patient treated. PseudoPatient® has already been awarded (R&D100 award, 1st prize in MIT Enterprise Forum), and has top-scored among the 250 initial participants and the 5 finalists of the Startup3 2020-21 programme.
In July 2019, our proposal gained the seal-of-excellence under the SME Inst. ph. II. Furthermore, more than 70 peer-revewed papers have already been published proving high appreciation by the scientific community of PseudoPatient® solution.
Additionally, the PseudoPatient® idea has attracted radiotherapy equipment manufacturers as a means of testing, commissioning and quality assurance (machine QA) tool (using treatment-simulation plans).
The production line is currently based in Athens utilizing 3D printing, CNC, and dosimetric gel-polymerized technologies.
RTsafe Holding Ltd. is established in Ireland which owns 100% of RTsafe P.C. (Greece), and RTsafe Inc. (USA). Company shareholders own shares only of the Holding entity, which owns 100% of the IP rights of the International Patent of the PseudoPatient® offering. Company has achieved to gain – apart from various awards - FDA 510(k) clearance for the US market and is ISO13485 and ISO9001 certified.